However, this pathway is frequently activated in human prostate cancer as a result of genetic alterations that include the biallelic loss of PTEN and activating mutations in AKT1 and PIK3CA/B [4-6, 10]. The gene discussed is AKT1; the disease is prostate carcinoma.